- Details
- Description
Packaging Size:
30c/Bottle
Strength:
15mg
Composition:
Golidocitinib
Treatment:
Adult patients with relapsed or refractory peripheral T-cell lymphoma (r/r PTCL)
Form:
Capsule
Brand:
高瑞哲
Quantity Unit:
0.15g*30c/Box
Manufacturer:
Dizal Pharma, China
Golidocitinib (DZD4205) is currently the first and only Janus kinase 1 (JAK1) selective inhibitor being evaluated for the treatment of r/r PTCL. In June 2024, golidocitinib was approved by the National Medical Products Administration (NMPA) of China for the treatment of adult patients with relapsed or refractory peripheral T-cell lymphoma (r/r PTCL).
- Golidocitinib sold under the brand name 高瑞哲® in china.
